Hardy Diagnostics has partnered with NG Biotech to exclusively distribute the 15-minute test in the US. It has also brought it through the US regulatory process.
According to Natera CEO Steve Chapman, the agreement will not detract from Natera's own efforts to establish its exome sequencing-based Signatera assay.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The test could potentially enable labs to bring resistance testing in house, rather than send testing out to Canada's National Microbiology Laboratory.
The project, called Seq&Treat, will be implemented in Brazil, China, Georgia, India, and South Africa starting in October.
The closure has no impact on the firm's other Los Gatos location, the original home of GeneWeave Biosciences, which Roche acquired in 2015 for up to $425 million.
The test is the fourth assay on the firm's Revogene system and it detects five common genetic causes of drug resistance.
Industry executives said that clinical needs associated with antimicrobial resistance and sepsis are generating more interest in AST technologies.
The PCR-based Carba assay is designed to detect and differentiate bacterial gene sequences that are associated with resistance to carbapenem antibiotics.
The funds will be used to support development and early marketing of a rapid test system for antibiotic resistance targeting patients with suspected sepsis.